2018 Funding Opportunity Announcement by Gilead Sciences Inc. and Kite, a Gilead Company

Background

Gilead Sciences Inc. is a leading biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. We strive to transform the promise of science and technology into therapies that have the power to cure diseases or revolutionize the standard of care.

Gilead and Kite, a Gilead Company are committed to pursuing cell therapies to advance cancer treatment. Over the past several decades, there has been important progress with the introduction of targeted therapies and, more recently, immunotherapy. Cell therapy — the use of genetically modified immune cells designed to target cancer cells — has the potential to build on those successes and improve outcomes for people living with certain types of cancer.

How Cell Therapy Works

Cell therapy is a cutting-edge approach that begins with collecting a patient’s own T cells through a process called leukapheresis. T cells, which are critical to the immune system’s ability to target cancer, sometimes fail to recognize and eliminate tumors. Engineered cell therapies are designed to respond to this problem by harnessing the power of a patient’s own immune system to more effectively target and attack cancer cells. A patient’s T cells are isolated and genetically engineered to make them more effective at targeting certain cancer cells. Through the manufacturing process, the engineered cells replicate and, once a sufficient number of cells are available, they are frozen, shipped to the cancer center where the patient is receiving treatment, and infused into the patient’s body where they can recognize and attack target cells, including cancer cells. This new approach has the potential to be particularly important for people with certain cancers who have not had success with other therapies.

Gilead’s determination to transform cancer treatment builds on more than 30 years of driving innovation in the treatment of HIV, liver diseases and other life-threatening conditions. We revolutionized HIV treatment by creating the world’s first once-daily, single-tablet regimen, and later changed the course of the hepatitis C epidemic with a new generation of therapies that offered unprecedented cure rates. Achieving these milestones required continuous innovation and persistence.
to advance treatments and improve outcomes. Today, we bring this same drive to our work in oncology.

Program Description

Realizing the promise of cell therapy and personalized medicine also requires a new approach to meeting the additional educational needs of caregivers, families and patients — in order to raise awareness of new treatment options and ultimately help improve the quality of health outcomes. As new treatments emerge, we strive to better understand and help address the practical challenges that patients face.

Through our giving programs, Gilead supports patient advocacy organizations, community organizations and healthcare entities around the world that work tirelessly to improve people’s lives. Through this funding opportunity award, we seek to support organizations in the United States that are finding innovative ways to help better educate those in need and to make a lasting, positive impact.

Gilead is accepting grant proposals in two distinct areas specific to cellular therapy:

1. **Outreach and education for patients, families and caregivers**

   Gilead seeks to support innovative educational programs that aim to improve patient engagement and patients’ experiences at critical junctures along the patient journey, especially where gaps have been identified by patients and families in treatment with cutting-edge CAR T therapy. Competitive programs should focus on the following types of activities:

   • Patient and family education about the treatment continuum
   • Resources to help patients and families navigate the healthcare journey
   • Communication tools to enhance the patient and provider relationship
   • After-care planning and palliative care resources

2. **Awareness, education and access to clinical trials**

   Gilead will consider proposals that focus on the role of clinical trials in advancing research or improving outcomes for late-stage cancer patients by addressing gaps in awareness, education, access and enrollment. Programs could include promising approaches to:

   • Raising awareness and understanding about clinical trials
   • Improving patient education about access to and participation in clinical trials
   • Improving patient and provider communication and engagement about clinical trials

**Eligibility**

Organization(s) must be classified as a not-for-profit and headquartered in the United States with an interest in public health, including but not limited to providing social services, education or advocacy for underserved populations. Collaborative submissions are encouraged.
**How to Apply**
Organizations are required to submit their requests using the online application form, which can be accessed by clicking [http://grants.gilead.com/](http://grants.gilead.com/). Please review the grant Terms and Conditions prior to submitting an application.
When submitting your application, please include “Gilead Lift” in the program title.

**Inquiries**
Questions about the announcement or application process should be submitted to grants@gilead.com.

**Key Dates and Deadlines**
Deadline to submit grant proposals: Friday, November 9, 2018
Intent to fund announcement by: December 10, 2018
Grant period begins: January 1, 2019
Midyear reports due: July 31, 2019

**Selection Criteria**
Successful proposals will clearly articulate how the program meets the following criteria:

- Ability to clearly articulate capacity and experience to fulfill requested program, should it be funded
- A focus on innovative educational approaches to address the current challenges faced by patients and families affected by cancer, specifically those who are seeking cutting-edge treatments such as CAR-T
- Staff expertise and experience that is in line with project scope
- A work plan that targets root causes, adheres to best practices, and sets clear and achievable goals
- A strategy for achieving the broadest reach and/or building an approach replicable on a broad scale
- A dissemination plan for sharing what is learned from grant-funded activities
- Original, innovative ideas and proven excellence in program development and implementation
- Appropriate and practical resources and budgets to support project goals

In addition, programs will be independent of Gilead and Kite, controlled solely by the grantee organization.

**Evaluation and Reporting**
Grantee organizations will be required to submit narrative and financial reports to Gilead for the purposes of monitoring progress toward project goals and ensuring budget adherence. Through the reporting process and related data collection, Gilead hopes to create opportunities to learn from both the successes and challenges faced by our partners, and to assess ways to increase the impact of future programs.

**Grant Awards**
Grant requests of up to $250,000 will be considered for a 12-month grant period beginning January 1, 2019. Budget requests should be proportional to organizational capacity and program scope, while reflecting reasonable, good-faith estimates of the true operational costs related to the proposed project. Indirect costs of 10 percent may be requested on top of direct program costs (see appendix A to learn more about Gilead’s indirect cost policy).
**Funding Restrictions**

Gilead funding cannot support:

- Medications or purchasing of medications
- Direct medical expenses, including labs
- Existing deficits
- Basic biomedical research, Gilead-sponsored clinical research or clinical trials
- Projects that directly influence or advance Gilead’s business, including purchase, utilization, prescribing, formulary position, pricing, reimbursement, referral, recommendation or payment for products
- Individuals, individual healthcare providers or physician group practices
- Events or programs that have already occurred
- Government lobbying activities
- Organizations that discriminate on the basis of race, color, gender, religion, disability, sexual orientation, or gender identity or expression

**Disclaimer Statement**

- Gilead reserves the right to approve or disapprove any application in its sole discretion.
- Award of a grant in any one cycle does not infer that a subsequent grant will be awarded without further application and approval.
- Application to the Corporate Grants program is not a promise of funding.

**About Gilead Sciences**

Gilead Sciences Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

**About Kite**

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor-engineered cell therapies. For more information on Kite, please visit www.kitepharma.com.
APPENDIX A - Indirect Cost Guidelines

Indirect costs are overhead expenses incurred by the applicant organization as a result of the project, but which are not easily identified with the specific project. Generally, indirect costs are defined as administrative or other expenses that are not directly allocable to a particular activity or project; rather, they are related to overall general infrastructure operations. Indirect costs are sometimes referred to as “overhead costs” and more recently by the government as “facilities and administrative costs.” Examples include executive oversight, accounting, grants management, legal expenses, utilities, technology support and facility maintenance.

Gilead prefers, whenever possible, that specific allocable costs of an applicant organization’s project should be requested and justified in the proposal as direct costs, including those for dedicated ongoing project management, facilities and support (further definitions are provided below).

As a company, we seek to fund the actual cost of the proposed project, and to support the efficiency and effectiveness needed for improving the care of patients living with life-threatening diseases around the world. Gilead will consider supporting a consolidated indirect cost fee on a case-by-case basis, provided that it comprises 10 percent or less of the total proposed project cost.

For the purpose of funding the grants, Gilead has established basic definitions and guidance to be used by our applicants and prospective applicants (see below).

Through our philanthropy and grants programs, Gilead does not match the indirect-cost rates that the federal government may pay to its applicants and contractors. We recognize that this means our applicants may need to engage in cost-sharing between projects, tap into unrestricted funds or conduct other fundraising activities to cover unbudgeted operation costs.

### Direct and Indirect Cost Definitions

<table>
<thead>
<tr>
<th>Direct Costs</th>
<th>Indirect Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>⇒ Salaries of employees directly attributable to the execution of the project</td>
<td>⇒ Facilities not acquired specifically and exclusively for the project (e.g., foundation, institute or university headquarters)</td>
</tr>
<tr>
<td>o Includes project management</td>
<td>⇒ Utilities for facilities not acquired for and not directly attributable to the project</td>
</tr>
<tr>
<td>o Includes administrative support solely dedicated to the project</td>
<td>⇒ Information technology equipment and support not directly attributable to the project</td>
</tr>
<tr>
<td>⇒ Fringe benefits of employees directly attributable to the execution of the project</td>
<td>⇒ General administrative support not directly attributable to the project. Examples are as follows:</td>
</tr>
<tr>
<td>o Includes project management</td>
<td>o Executive administrators</td>
</tr>
<tr>
<td>o Includes administrative support solely dedicated to the project</td>
<td>o General ledger accounting</td>
</tr>
<tr>
<td>⇒ Travel for employees directly attributable to the execution of the project</td>
<td>o Grants accounting</td>
</tr>
<tr>
<td>⇒ Consultants whose work is directly attributable to the execution of the project</td>
<td>o General financial management</td>
</tr>
<tr>
<td>⇒ Supplies directly attributable to the execution of the project</td>
<td>o Internal audit functions</td>
</tr>
<tr>
<td>⇒ Subawards directly attributable to the execution of the project</td>
<td>o IT support personnel</td>
</tr>
<tr>
<td>⇒ Subcontracts directly attributable to the execution of the project</td>
<td>o Facilities support personnel</td>
</tr>
<tr>
<td>⇒ Equipment acquired for and directly attributable to the execution of the project</td>
<td>o Scientific support functions (not attributable to the project)</td>
</tr>
<tr>
<td>⇒ Facilities newly acquired and specifically used for the grant project (excludes existing facilities)</td>
<td>o Environment health and safety personnel</td>
</tr>
<tr>
<td>Examples include:</td>
<td>o Human resources</td>
</tr>
<tr>
<td>o A new field clinic</td>
<td>o Library and information support</td>
</tr>
<tr>
<td>o New testing laboratories</td>
<td>o Shared procurement resources</td>
</tr>
<tr>
<td>o Project implementation unit office</td>
<td>o General logistics support</td>
</tr>
<tr>
<td></td>
<td>o Material management</td>
</tr>
<tr>
<td></td>
<td>o Executive management</td>
</tr>
<tr>
<td></td>
<td>o Other shared resources not directly attributable to the project</td>
</tr>
<tr>
<td>Utilities for facilities acquired for and directly attributable to the execution of the project</td>
<td></td>
</tr>
<tr>
<td>Information technology acquired for and directly attributable to the execution of the project</td>
<td></td>
</tr>
<tr>
<td>Internal legal and/or accounting staff and/or external legal counsel or accountants directly attributable to the project</td>
<td></td>
</tr>
</tbody>
</table>

- Institutional legal support
- Research management costs
- Depreciation on equipment
- Insurance not directly attributable to a given project